Stem cell therapy for ulcerative colitis
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon and rectum. Mesenchymal stem cell therapy is discussed as immune-modulating support for patients whose disease remains active despite standard treatment — alongside, not instead of, gastroenterology care.
Why MSCs are studied in inflammatory bowel disease
MSCs suppress excessive T-cell activity, shift macrophages toward a repair phenotype and support mucosal healing. The most established evidence in IBD is for perianal fistulising Crohn's disease, where a licensed MSC product exists in Europe. Ulcerative colitis data are earlier-stage, which is stated plainly in consultation.
Related pathway: stem cell therapy for Crohn's disease.
Evidence at a glance — Ulcerative colitis
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — early-stage only
- Randomised trials?
- Few randomised trials
- Main outcomes studied
- Clinical remission
- Endoscopic healing
- Mayo score
- Safety
- Long-term evidence
- Very limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — Ulcerative colitis — PubMed
- Randomised controlled trials — Ulcerative colitis — PubMed
- Registered MSC trials — Ulcerative colitis — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
Who is considered
Patients most often discussed are those with moderate to severe disease that is steroid-dependent or has lost response to biologics, who are under active gastroenterology follow-up and whose current disease activity is documented endoscopically.
- Confirmed UC diagnosis with recent colonoscopy and histology
- Documented response and failure history for current therapies
- No active severe infection, malignancy or toxic megacolon
- Willingness to continue specialist monitoring after returning home
Realistic goals
Objectives are framed as reduced flare frequency, lower inflammatory markers, better symptom control and — where possible — steroid reduction under gastroenterology supervision. Endoscopic remission is not promised.
Delivery and monitoring
Intravenous infusion is the usual route for systemic immune modulation. Monitoring uses symptom scores, faecal calprotectin and CRP at defined intervals, with results shared with your home team — see the 3/6/12-month follow-up framework.
Frequently asked questions
Can stem cells cure ulcerative colitis?
No. UC is a chronic relapsing condition. The realistic aim is better disease control, and evidence in UC specifically is still developing.
Should I stop my biologic or mesalazine?
No. Medication decisions stay with your gastroenterologist. Any tapering is their call, based on documented response.
Is treatment appropriate during a severe flare?
Usually not. Acute severe colitis needs urgent conventional management first.
Ask whether this is right for you
Share your diagnosis and recent records. Our medical team in Istanbul reviews candidacy, alternatives and realistic goals before any treatment plan is proposed.
Request a free medical review